[NCHC] AEI Session on Financing Cures: White Hat or White Wash?

07-10-2014 Press Release

On Friday, July 11, AEI is hosting a session entitled “How will we pay for the cost of cures?” On its face this seems like a laudatory endeavor.  After all, as a society we need to ensure we have adequate financing mechanisms for medical innovation.  However, there is a risk that the panelists avoid the […]

[NCHC] New York Joins List of States Outraged Over Sovaldi

06-30-2014 Press Release

Costs to New Yorkers for One Drug Is 4 Times Entire Higher Education Spending A recent article in Capital New York  highlights the dilemma posed by Gilead’s new Hepatitis C drug, Sovaldi.  While an important new therapy for patients the drug has been priced in such a way that it threatens to undermine the public […]

[Vox.com] The fiercest debate in health care is about a $1,000 pill

05-28-2014 Press Release

“The people who pay for drugs aren’t fully buying those arguments — and want Sovaldi to back off its prices. They argue that Gilead could more than cover the costs of drug development and even run a profit with a lower price. This year alone, analysts expect Sovaldi to generate as much as $15 billion […]

[Kaiser Health News] ‘National Dialogue’ Urged On Cost Of New Hepatitis C Drug

05-28-2014 Press Release

“The outcry continues over the $1,000-a-pill hepatitis C drug made by California-based Gilead Sciences. While the drug is a significant advance over older treatments for the viral liver disease, the price set by the company ‘represents an abuse of market power,’ said John Rother, president and CEO of the National Coalition on Health Care, which […]

[POLITICO Pulse] NEW COALITION TARGETS SOLVADI COST

05-28-2014 Press Release

“A broad coalition of health care groups is trying to compel the pharmaceutical company Gilead to slim down its profits on the multibillion-dollar hepatitis drug. The “miracle” med costs about $84,000 for a 12-week treatment that effectively cures hepatitis C more than 90 percent of the time — far more effective than earlier drugs that […]

[POLITICO Pro] 80-group campaign targeting hepatitis drug cost

05-28-2014 MediaPress Release

“More than 80 organizations are launching the Campaign for Sustainable Rx Pricing to bring the pharmaceutical company Gilead to the table to negotiate a lower price, hoping that public pressure will prevail where private entreaties have not. John Rother, CEO of the National Coalition on Health Care, said Gilead’s pricing amounts to ‘an abuse of […]

[CNBC] The $84,000 question: Will focusing on drug prices rein in costs?

05-22-2014 Press Release

By Meg Tirrell May 22, 2014   The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch when a new drug for hepatitis C was priced at about $1,000 a day. Gilead Sciences’ Sovaldi, approved in December, cures the viral liver infection in most cases. it takes about 12 weeks, and costs […]

[MedPage Today] Medicaid Directors Question Need for $1,000 HCV Pill

05-22-2014 Press Release

By Michael Smith May 22, 2014   The evidence base for one of the star hepatitis C drugs is poor and the guidelines for its use are flawed, according to a report prepared for the National Association of Medicaid Directors. According to the report, studies of sofosbuvir (Sovaldi) are generally of poor quality, mostly directed […]

[Politico] No consensus on how to afford specialty drugs

05-21-2014 Press Release

By Brett Norman May 21, 2014 The astronomical price of a new “miracle” drug for hepatitis C has insurers and others who ultimately foot health care bills agreeing that drug costs are out of control and must come down. But there’s little consensus on how to make that happen. Executives from insurers, pharmacy benefit managers […]

[Inside Health Policy] Spurred By Sovaldi’s Price, Drug Makers & Plans Consider Mortgaging Pricey Drugs

05-21-2014 Press Release

By John Wilkerson May 21, 2014   Spurred by the prospect of Sovaldi’s high cost, some policy wonks are talking about letting plans and state Medicaid agencies spread the cost of expensive drugs out over several years, much like a mortgage. The idea is in the early stages of discussion, and no trade group, politician […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.